Comparison
Exenatide vs. SNAP-8
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Cosmetic
CAS no.
141758-74-9
868844-74-0
Molecular weight
4186.6 g/mol
1075.16 g/mol
Half-life
2.4 h
no data
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSAc-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Mechanism of action
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
3
of which in humans
4
1
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
2
1